Antimony Plus Pentoxifylline in Cutaneous Leishmaniasis

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

164

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

January 31, 2015

Study Completion Date

October 31, 2015

Conditions
Cutaneous Leishmaniasis
Interventions
DRUG

Pentoxifylline

Patients with cutaneous leishmaniasis treated with pentavalent antimony/Meglumine antimoniate 20mg/kg/day during 20 days and pentoxifylline pills 400mg three times a day during 20 days.

DRUG

Placebo

Patients with cutaneous leishmaniasis treated with pentavalent antimony/metilglucamine 20mg/kg/day during 20 days and placebo pills three times a day during 20 days.

Trial Locations (1)

40000

Posto de Saúde de Corte de Pedra, Corte de Pedra

All Listed Sponsors
collaborator

Instituto Nacional de Ciência e Tecnologia de Doenças Tropicais (INCT-DT)

UNKNOWN

collaborator

Conselho Nacional de Desenvolvimento Científico e Tecnológico

OTHER_GOV

collaborator

Federal University of Bahia

OTHER

lead

Paulo Roberto Lima Machado

OTHER

NCT01381055 - Antimony Plus Pentoxifylline in Cutaneous Leishmaniasis | Biotech Hunter | Biotech Hunter